Search Results (520)
Click the Why column to see why an item matched the search.

MatchTypeWhy
Munshi, Nikhil C.Person Why?
Genomic patterns of progression in smoldering multiple myeloma.Academic Article Why?
Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.Academic Article Why?
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.Academic Article Why?
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.Academic Article Why?
A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.Academic Article Why?
A clinically relevant SCID-hu in vivo model of human multiple myeloma.Academic Article Why?
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.Academic Article Why?
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.Academic Article Why?
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.Academic Article Why?
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.Academic Article Why?
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.Academic Article Why?
Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.Academic Article Why?
ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning.Academic Article Why?
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.Academic Article Why?
First Prev Page of 35 Next Last Per PageĀ 
Highlights
Search Criteria
  • Multiple Myeloma
Filter by Type